Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) EBITDA (2019 - 2023)

Alx Oncology Holdings' EBITDA history spans 5 years, with the latest figure at $88.5 million for Q4 2023.

  • For Q4 2023, EBITDA rose 374.64% year-over-year to $88.5 million; the TTM value through Dec 2023 reached -$33.8 million, up 73.5%, while the annual FY2025 figure was -$21.4 million, 24.59% up from the prior year.
  • EBITDA for Q4 2023 was $88.5 million at Alx Oncology Holdings, up from -$53.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $88.5 million in Q4 2023 and bottomed at -$53.3 million in Q3 2023.
  • The 5-year median for EBITDA is -$15.3 million (2021), against an average of -$10.9 million.
  • The largest annual shift saw EBITDA plummeted 223.3% in 2020 before it soared 374.64% in 2023.
  • A 5-year view of EBITDA shows it stood at -$3.0 million in 2019, then surged by 636.68% to $16.3 million in 2020, then surged by 130.61% to $37.6 million in 2021, then plummeted by 185.8% to -$32.2 million in 2022, then soared by 374.64% to $88.5 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's EBITDA are $88.5 million (Q4 2023), -$53.3 million (Q3 2023), and -$36.8 million (Q2 2023).